{
  "pmcid": "8675044",
  "sha256": "57de33843b6b16b9d1ec2f04eebaad4847d8e8b970cb035bf8eb7de58389d7f2",
  "timestamp_utc": "2025-11-09T16:18:53.599706+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 14.015933609958509,
    "reading_ease": 27.594395148420062,
    "word_count": 241
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "In this randomized, double-blind, placebo-controlled, dose-ranging study"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "randomly assigned, in a 1:1:1:1 ratio"
      },
      "Participants": {
        "score": 2,
        "evidence": "120 otherwise healthy adults who underwent the extraction of bilateral impacted mandibular third molar teeth and experienced moderate to severe pain postsurgery"
      },
      "Intervention": {
        "score": 2,
        "evidence": "to receive one dose of either placebo or DFN-15 at 3 doses: 62.5, 125, and 250 mg"
      },
      "Objective": {
        "score": 1,
        "evidence": "The analgesic efficacy and safety of DFN-15, a new oral liquid formulation of celecoxib with more rapid absorption than the capsule, were evaluated in the treatment of acute pain in adult patients after dental surgery."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary endpoint was the summed pain intensity difference (SPID) over the 6-hour postdose period (SPID6)"
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "randomly assigned, in a 1:1:1:1 ratio"
      },
      "Blinding": {
        "score": 2,
        "evidence": "double-blind"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "120 otherwise healthy adults"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "All 3 doses of DFN-15 were significantly superior to placebo in SPID6 (least square mean difference over placebo: −756.6, −1120.7, and −1355.1, P < 0.0001 for all comparisons)."
      },
      "Harms": {
        "score": 1,
        "evidence": "DFN-15 was similar to placebo in the incidence of adverse events with no apparent dose-related effects."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 17,
    "max_score": 25
  }
}